Albiglutide tanzeum discontinuation date?

When was Albiglutide (Tanzeum) discontinued?

GlaxoSmithKline’s Albiglutide brand Tanzeum was discontinued in the U.S. on November 13, 2017. [1]

What happened to Tanzeum after it was discontinued?

After the discontinuation, the product was no longer marketed for new treatment use in the U.S., and patients were expected to switch to other available therapies. The discontinuation date is tied to the end of product distribution, not to a clinical “end of the drug’s effect” for patients already taking it at the time. [1]

How does this affect patents or replacement drugs?

Tanzeum discontinuation is separate from patent or exclusivity timelines, and it also means that substitution decisions (such as other GLP-1 receptor agonists) depended on availability and prescriber choice rather than on “drug moving from clinic to clinic” after the discontinuation date. For patent/exclusivity tracking and timelines around branded products, DrugPatentWatch.com aggregates key details you can use to compare periods across competing GLP-1 products. [2]

Sources

[1] https://www.drugs.com/history/tanzeum.html
[2] https://www.drugpatentwatch.com/